Go Pro
→ Trump’s New Currency Reset (From Porter & Company) (Ad)tc pixel
NASDAQ:INVA

Innoviva Q3 2024 Earnings Report

Innoviva logo
$20.68 +0.17 (+0.83%)
As of 04:00 PM Eastern
ProfileEarnings HistoryForecast

Innoviva EPS Results

Actual EPS
$0.02
Consensus EPS
$0.27
Beat/Miss
Missed by -$0.25
One Year Ago EPS
N/A

Innoviva Revenue Results

Actual Revenue
$89.51 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Innoviva Announcement Details

Quarter
Q3 2024
Date
11/6/2024
Time
After Market Closes
Conference Call Date
Tuesday, November 5, 2024
Conference Call Time
6:00PM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Innoviva's Q3 2024 Press ReleasePress Release
(8-K)
Innoviva's Q3 2024 Quarterly reportQuarterly report
(10-Q)

Innoviva Earnings Headlines

Innoviva Inc Share Price (INVA.US)
August 7 at 5:55 PM  |  lse.co.ukhttps://www.lse.co.uk/SharePrice.html?shareprice=INVA.US&mobile_view=desktop
Innoviva, Inc. (INVA) latest stock news and headlines – Yahoo Finance
August 6, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/quote/INVA/news/?ltr=1
BofA: Digital Dollar Coming 2025-2030
If you've got $50k+ sitting in a bank account, you need to hear this. There's a plan to merge every dollar you own, every transaction you make, and every asset you hold onto ONE global ledger. Back in 2020 they said the quiet part out loud... "The central bank will have absolute control." The plan is one global ledger. Every dollar you own... Every transaction you make... All on one platform. Visible. Programmable. But here's what they don't tell you... A loophole already exists that allows you to opt out. A parallel system, outside the traditional banking rails. Outside the ledger. Visa moved billions of transactions onto it last year. PayPal built its entire new payment layer on top of it. BlackRock chose it as the home for their first tokenized fund. The people who run the system... are quietly stepping outside it.tc pixel
August 10 at 1:00 AM  |  Decentralized Masters (Ad)
Innoviva: The Royalty Decline Is Real, But The Valuation Is Too Pessimistic
August 6, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4931656-innoviva-the-royalty-decline-is-real-but-the-valuation-is-too-pessimistic
Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
August 5, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260805369250/en/innoviva-reports-second-quarter-2026-financial-results-highlights-recent-company-progress/
Innoviva, Inc. (NASDAQ:INVA) Receives $36.20 Average Price Target from Analysts
August 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30934130
See More Innoviva Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Innoviva? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Innoviva and other key companies, straight to your email.

About Innoviva

Innoviva (NASDAQ:INVA), incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle. Since its formation, Innoviva has supplemented its core royalty stream with additional licensing and collaboration agreements, and has pursued disciplined capital‐allocation activities to maximize dividend payments to shareholders. The firm’s contractual arrangements typically provide for tiered royalties on net sales as well as potential milestone receipts upon regulatory approvals and commercial launches.

Innoviva’s royalty revenues are generated globally through collaboration partners that market, distribute and promote the underlying therapeutics both in the United States and in international territories. The company maintains a lean corporate structure, relying on third‐party manufacturing, regulatory and commercialization expertise. Innoviva is governed by an experienced board of directors and led by management professionals with backgrounds in pharmaceutical licensing, royalty financing and capital markets.

View Innoviva Profile
Earnings Tools